

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference SLI-003WO	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/US2020/060176	International filing date (<i>day/month/year</i>) 12 November 2020 (12-11-2020)	(Earliest) Priority Date (<i>day/month/year</i>) 12 November 2019 (12-11-2019)
Applicant GENZYME CORPORATION		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of:

- ☒ the international application in the language in which it was filed
☐ a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

b. ☐ This international search report has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43.6**bis**(a)).

c. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐ **Certain claims were found unsearchable** (See Box No. II)

3. ☐ **Unity of invention is lacking** (see Box No III)

4. With regard to the **title**,

- ☐ the text is approved as submitted by the applicant
☒ the text has been established by this Authority to read as follows:

6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

5. With regard to the **abstract**,


- ☐ the text is approved as submitted by the applicant
☒ the text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority

6. With regard to the **drawings**,

- a. the figure of the **drawings** to be published with the abstract is Figure No. _____
☐ as suggested by the applicant
☐ as selected by this Authority, because the applicant failed to suggest a figure
☐ as selected by this Authority, because this figure better characterizes the invention
b. ☐ none of the figures is to be published with the abstract

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFT'R activity, in particular cystic fibrosis.



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2020/060176

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D213/75 A61P11/00 C07D239/69 C07D241/22 C07D403/04
C07D403/12 A61K31/495

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006/113704 A2 (NEUROGEN CORP [US]; YUAN JUN [US] ET AL.) 26 October 2006 (2006-10-26) examples RN 913281-02-4, CN Benzenesulfonamide, 4-chloro-N-[6-(3-chloro-4-pyridinyl)-5-[4- (trifluoromethyl)phenyl]-2-pyrazinyl]- claims ----- -/-	1-29,31, 33-37, 39-44, 46-48



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

20 January 2021

Date of mailing of the international search report

29/01/2021

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Stix-Malaun, Elke

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2020/060176

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/24782 A2 (AMGEN INC [US]; SPOHR ULRIKE D [US] ET AL.) 11 June 1998 (1998-06-11) examples RN 208935-39-1 ,CN Benzenesulfonamide, 4-amino-N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-2-pyrimidinyl]-; RN 208935-41-5,CN Benzenesulfonamide, 4-amino-N-[5-(4-fluorophenyl)-4-(4-pyridinyl)-2-pyrimidinyl]- claims -----	1-29,31, 33-37, 39-44, 46-48
X	SHIN YOSHII ET AL: "Antiviral and Antibacterial Activities of 3-(Substituted benzenesulfonylamino)-5, 6-di(p-substituted phenyl)-1, 2, 4-triazines", THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 108, no. 1, 1 January 1988 (1988-01-01), pages 50-57, XP055766841, ISSN: 0031-6903, DOI: 10.1248/yakushi1947.108.1_50 page 54; examples -----	1-29,31, 33-37, 39-44, 46-48
X	HARUO SAIKACHI ET AL: "Synthesis of the Furan Derivatives. XLVII. : Synthesis of 5, 6-Bis (5-nitro-2-furyl)-2-aminopyrazine and Its Related Compound", THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 89, no. 8, 1 January 1969 (1969-01-01), pages 1071-1077, XP055766986, ISSN: 0031-6903, DOI: 10.1248/yakushi1947.89.8_1071 page 1074; compounds -----	1-29,31, 33-37, 39-44, 46-48
A	WO 2018/042316 A1 (NOVARTIS AG [CH]) 8 March 2018 (2018-03-08) examples claims -----	1-56
A	WO 2019/161078 A1 (VERTEX PHARMA [US]) 22 August 2019 (2019-08-22) cited in the application examples claims -----	1-56
A,P	WO 2020/206080 A1 (VERTEX PHARMA [US]) 8 October 2020 (2020-10-08) examples claims -----	1-56

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2020/060176

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006113704	A2	26-10-2006	AR 053712 A1 16-05-2007
		AU 2006236387 A1 26-10-2006	
		CA 2606288 A1 26-10-2006	
		EP 1871762 A2 02-01-2008	
		JP 2008536950 A 11-09-2008	
		TW 200716594 A 01-05-2007	
		US 2007078135 A1 05-04-2007	
		WO 2006113704 A2 26-10-2006	
WO 9824782	A2	11-06-1998	AR 038955 A1 02-02-2005
		JP 2002514195 A 14-05-2002	
		TW 520362 B 11-02-2003	
		WO 9824782 A2 11-06-1998	
WO 2018042316	A1	08-03-2018	AR 109437 A1 28-11-2018
		AU 2017319430 A1 14-02-2019	
		BR 112019003883 A2 18-06-2019	
		CA 3031073 A1 08-03-2018	
		CN 109641873 A 16-04-2019	
		EA 201990609 A1 31-07-2019	
		EP 3504194 A1 03-07-2019	
		JP 2019530739 A 24-10-2019	
		KR 20190040319 A 17-04-2019	
		TW 201811766 A 01-04-2018	
		US 2018072673 A1 15-03-2018	
		US 2020002281 A1 02-01-2020	
		UY 37379 A 23-03-2018	
		WO 2018042316 A1 08-03-2018	
WO 2019161078	A1	22-08-2019	AR 114254 A1 12-08-2020
		AU 2019222758 A1 13-08-2020	
		CA 3088577 A1 22-08-2019	
		CN 112004817 A 27-11-2020	
		CR 20200403 A 26-10-2020	
		EP 3752510 A1 23-12-2020	
		KR 20200131240 A 23-11-2020	
		SG 11202006614V A 28-08-2020	
		TW 201938566 A 01-10-2019	
		US 2019248809 A1 15-08-2019	
		UY 38093 A 01-10-2019	
		WO 2019161078 A1 22-08-2019	
WO 2020206080	A1	08-10-2020	NONE